EHA25Virtual: Promising Treatment Results with Imetelstat, a Novel Telomerase Inhibitor, in Patients with Lower Risk Myelodysplastic Syndromes

EHA25Virtual: Promising Treatment Results with Imetelstat, a Novel Telomerase Inhibitor, in Patients with Lower Risk Myelodysplastic Syndromes

PR Newswire

THE HAGUE, Netherlands, June 12, 2020

THE HAGUE, Netherlands, June 12, 2020 /PRNewswire/ -- IMerge is a Phase 2/3 clinical trial evaluating imetelstat as a treatment for patients with lower risk myelodysplastic syndromes (MDS)that are non-del(5q), dependent on red blood cell transfusion, and are relapsed after or refractory to treatment with erythropoiesis stimulating agents.

EHA Logo (PRNewsfoto/European Hematology Association)

The primary efficacy endpoint of IMerge is 8-week red blood cell transfusion independence (RBC-TI) rate, defined as the proportion of patients not receiving any RBC transfusion during any consecutive eight weeks since entry into the trial. This presentation reports long-term efficacy and safety data from 38 patients in the IMerge Phase 2 clinical trial, based on a February 4, 2020 cut-off date and a median follow-up of 24 months:

The Phase 3 double-blind, placebo-controlled stage of IMerge is currently recruiting patients and is ongoing.

Presenter: Dr Uwe Plazbecker
Affiliation: Department of Hematology and Cell Therapy, University Clinic Leipzig, Germany
Abstract: #S183 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESA)

About the EHA Annual Congress: Every year in June, EHA organizes its Annual Congress in a major European city. Due to the COVID19 pandemic, the physical meeting was transformed into a Virtual Congress this year. Please note that our embargo policy applies to all selected abstracts in the Press Briefings. For more information, see our EHA Media and Embargo policy here.

Logo - http://mma.prnewswire.com/media/622259/EHA_Logo.jpg

 

Voltar noticias em Inglês